ResMed
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Mid-pack momentum — held if you own it, not a fresh buy.
- Signal has read HOLD for 2 days.
- Recent price momentum is +0.5% on average (3-month/1-year).
- Main-fund capital flow has been a net outflow over the last 45 sessions.
- Short interest has fallen to 7.4% of float.
- Analyst tilt is Buy.
- Price is below its 20-day average and above its 60-day average.
- The 20-day average is above the 60-day average, a short-term uptrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 2848 U.S. stocks StockVane covers.
Last computed: 2026-11-22 02:27 UTC
Data coverage: 6 of 6 factors. Missing data is not a zero score.
Valuation C+
How expensive the stock is versus earnings, sales and its own 5-year history.
| P/E (TTM) | 21.5x | Better than 38% |
| Forward P/E | 19.4x | Better than 38% |
| Price / Sales | 5.8x | Better than 19% |
| P/E vs own 5-yr range | 7th pctl | Better than 93% |
Growth A-
How fast revenue, profit and free cash flow are compounding.
| Revenue CAGR (3Y) | 10.2% | Better than 65% |
| Net income CAGR (3Y) | 19.3% | Better than 72% |
| Free cash flow CAGR (3Y) | 42.8% | Better than 82% |
Profitability A
How much profit the business keeps from each dollar of sales and capital.
| Gross margin | 61.1% | Better than 75% |
| Operating margin | 33.8% | Better than 92% |
| Net margin | 26.9% | Better than 87% |
| Return on equity | 24.3% | Better than 83% |
| Return on invested capital | 21.4% | Better than 91% |
Momentum B+
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | 2.1% | Better than 78% |
| 6-month return | 13.9% | Better than 77% |
| 12-month return (ex latest month) | 1.7% | Better than 36% |
| Distance below 52-week high | 14.2% | Better than 74% |
Financial Health A-
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 3.1x | Better than 74% |
| Debt to assets | 9.2% | Better than 71% |
| Interest coverage | 28.7x | Better than 86% |
| Free cash flow / net income | 106.9% | Better than 43% |
Analyst View C-
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 50.0% | Better than 26% |
| Upside to average target | 16.4% | Better than 26% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.
Performance
Key statistics
Price & volume
- Prev close
- 236.88
- Open
- 237.18
- Day range
- 234.70 - 242.43
- Avg price
- 237.26
- Volume
- 1.37M
- Turnover
- 325.02M
- Turnover ratei
- 0.98%
- Volume ratioi
- 1.17
- Amplitudei
- 3.26%
- 52-week rangei
- 179.25 - 274.65
Valuation
- P/Ei
- 22.59
- P/E (TTM)i
- 21.46
- P/Bi
- 5.57
- EPSi
- 10.43
- Book value / shi
- 42.29
- Net profit
- 1.47B
- Net assets
- 5.95B
Share structure
- Market cap
- 33.14B
- Float capi
- 32.94B
- Shares out
- 140.66M
- Float sharesi
- 139.80M
Dividend & listing
- Div yield (TTM)i
- 1.04%
- Dividend (TTM)
- 2.46
- Listing date
- 1970-01-01
14.2% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-49.66M net over the window
Short interest
- Shares short
- 10.47M
- % of floati
- 7.44%
- Days to coveri
- 7.05
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of ResMed (RMD)?
ResMed last traded at 235.63. This page shows a periodic quote snapshot. Check the displayed quote time.
What is ResMed's market cap?
About 33.14B.
What is the P/E ratio of ResMed?
The trailing twelve-month P/E is 21.46, below its own 5-year average of 34.19 — toward the bottom of its historical range (7.41% percentile). See the Valuation tab for the full history.
Does ResMed pay a dividend?
Yes. The trailing dividend yield is 1.04%. The 2025 payout was up 11.9% from 2024. See the Dividends tab for the full payment history.
Is ResMed a buy according to analysts?
The consensus of 8 analysts is a Buy rating, with an average 12-month price target of 274.29, which implies 16.4% upside from the current price. This is not investment advice.
What is ResMed's StockVane Quant Rating?
The StockVane Momentum strategy currently rates ResMed a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.
Quote time 2026-11-20 20:01:25 · For reference only, not investment advice and not tailored to your situation.
ResMed discussion 0 comments